SG11201502816YA - Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics - Google Patents
Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeuticsInfo
- Publication number
- SG11201502816YA SG11201502816YA SG11201502816YA SG11201502816YA SG11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA
- Authority
- SG
- Singapore
- Prior art keywords
- production
- recombinant antibody
- signal peptides
- antibody therapeutics
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG11201502816YA SG11201502816YA (en) | 2012-10-12 | 2013-08-21 | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG2012076295 | 2012-10-12 | ||
| SG11201502816YA SG11201502816YA (en) | 2012-10-12 | 2013-08-21 | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| PCT/SG2013/000360 WO2014058389A1 (en) | 2012-10-12 | 2013-08-21 | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502816YA true SG11201502816YA (en) | 2015-05-28 |
Family
ID=50477711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502816YA SG11201502816YA (en) | 2012-10-12 | 2013-08-21 | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10066019B2 (de) |
| EP (1) | EP2906599B1 (de) |
| CN (1) | CN104854133B (de) |
| SG (1) | SG11201502816YA (de) |
| WO (1) | WO2014058389A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014058389A1 (en) | 2012-10-12 | 2014-04-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| KR102092225B1 (ko) | 2014-04-30 | 2020-03-23 | 주식회사 엘지화학 | 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터 |
| CN105820246A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途 |
| US10830780B2 (en) * | 2015-01-26 | 2020-11-10 | Biotech Institute, Llc | Apparatus and methods for sample analysis and classification based on terpenes and cannabinoids in the sample |
| WO2016120753A1 (en) * | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| KR20220119529A (ko) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
| AU2017287743C1 (en) * | 2016-06-30 | 2020-10-01 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| WO2019055471A1 (en) * | 2017-09-18 | 2019-03-21 | Amyris, Inc. | METHODS FOR PRODUCING FULL LENGTH ANTIBODIES |
| CN107488636A (zh) * | 2017-09-30 | 2017-12-19 | 山东兴瑞生物科技有限公司 | 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用 |
| ES2877659T3 (es) | 2017-12-01 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides y sus inmunoconjugados |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| US11447547B1 (en) * | 2017-12-13 | 2022-09-20 | Amgen Inc. | Method of antigen-binding protein production |
| CN108103088B (zh) * | 2017-12-21 | 2021-03-26 | 广东东阳光药业有限公司 | 重组GLP-1类似物Fc融合蛋白的优化基因及其应用 |
| BR112021012065A2 (pt) | 2018-12-21 | 2021-12-07 | Kymab Ltd | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| CN113939541A (zh) * | 2019-05-15 | 2022-01-14 | 科马布有限公司 | 改进的λ抗体 |
| CN111072764A (zh) * | 2019-12-13 | 2020-04-28 | 东莞市东阳光生物药研发有限公司 | 一种重组人Activin A的制备方法 |
| SE544006C2 (en) * | 2020-03-17 | 2021-11-02 | Xbrane Biopharma Ab | Novel combination of tis sequence and signal peptide sequence for expressing a recombinant protein |
| SE543998C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Dna construct for expressing nivolumab |
| AU2021239744B2 (en) * | 2020-03-17 | 2023-01-19 | Xbrane Biopharma Ab | Novel combination of TIS sequence and signal peptide sequence for expressing a recombinant protein |
| SE543999C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Dna construct for expressing a novel signal peptide |
| KR102457344B1 (ko) * | 2020-06-22 | 2022-10-24 | 건국대학교 글로컬산학협력단 | 항암 펩티드와 결합된 항원결합단편 플랫폼 |
| JP2023539581A (ja) * | 2020-08-28 | 2023-09-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| SE545694C2 (en) * | 2021-09-24 | 2023-12-05 | Xbrane Biopharma Ab | Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides |
| SE545714C2 (en) * | 2021-09-24 | 2023-12-19 | Xbrane Biopharma Ab | Dna contructs for producing a pelb signal peptide |
| WO2023081733A1 (en) * | 2021-11-02 | 2023-05-11 | Washington University | Compositions and methods of treatment for cancers |
| WO2023220118A2 (en) * | 2022-05-10 | 2023-11-16 | Regenerative Research Foundation | Compositions and methods for controlled protein degradation in neurodegenerative disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506132A (en) | 1993-07-28 | 1996-04-09 | Sandoz Pharmaceuticals Corporation | Human antibodies against varicella-zoster virus |
| MXPA04009418A (es) | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| AU2003282667A1 (en) * | 2002-10-03 | 2004-04-23 | Large Scale Biology Corporation | Multimeric protein engineering |
| CN103880955A (zh) | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
| TW200732472A (en) * | 2005-10-21 | 2007-09-01 | Hoffmann La Roche | Method for the recombinant expression of a polypeptide |
| US20090208491A1 (en) | 2007-02-14 | 2009-08-20 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
| EP3385279B1 (de) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Träger-immunglobuline und verwendungen davon |
| US20110150861A1 (en) * | 2009-10-30 | 2011-06-23 | Abbott Laboratories | Sorf constructs and multiple gene expression |
| WO2014058389A1 (en) | 2012-10-12 | 2014-04-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
-
2013
- 2013-08-21 WO PCT/SG2013/000360 patent/WO2014058389A1/en active Application Filing
- 2013-08-21 CN CN201380064541.4A patent/CN104854133B/zh active Active
- 2013-08-21 US US14/435,094 patent/US10066019B2/en active Active
- 2013-08-21 SG SG11201502816YA patent/SG11201502816YA/en unknown
- 2013-08-21 EP EP13845618.1A patent/EP2906599B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150225482A1 (en) | 2015-08-13 |
| EP2906599A4 (de) | 2016-04-27 |
| EP2906599B1 (de) | 2019-07-17 |
| CN104854133A (zh) | 2015-08-19 |
| US10066019B2 (en) | 2018-09-04 |
| WO2014058389A1 (en) | 2014-04-17 |
| EP2906599A1 (de) | 2015-08-19 |
| CN104854133B (zh) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201502816YA (en) | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics | |
| IL287270A (en) | Anti-psgl-1 antibodies and their use | |
| IL292121A (en) | Anti-plasma kallikrein antibodies | |
| HK1206636A1 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| HK1210027A1 (en) | Anti-human b7-h4 antibodies and their uses b7-h4 | |
| IL230918A0 (en) | Modified proteins and peptides | |
| HK1201296A1 (en) | Modified fc region of antibody fc | |
| IL224441B (en) | Antibodies with modified isoelectric points | |
| EP2904093A4 (de) | Verfahren zur quantitativen bestimmung von schwer- und leichtkettigen polypeptidpaaren | |
| HK1215446A1 (zh) | 抗體及其用途 | |
| EP2832855A4 (de) | Neuartiger anti-siglec-15-antikörper | |
| HK1208810A1 (en) | C-terminal and central epitope a-beta antibodies c a- | |
| EP2726103A4 (de) | Antikörper gegen properdin und verwendungen davon | |
| SG11201403814RA (en) | Production of recombinant proteins with simple glycoforms | |
| HK1222871A1 (zh) | 具有最小單體分離的重組多克隆抗體多聚體的分離 | |
| HK1220492A1 (zh) | 重組多肽生產 | |
| EP2678440A4 (de) | Hefestamm zur herstellung von proteinen mit modifizierter o-glycosylierung | |
| IL234394A0 (en) | Recombinant antibodies with dual specificity for gangliosides and their use | |
| EP2688913A4 (de) | Hochleistungsproduktion rekombinanter proteine | |
| EP2771689A4 (de) | Usp2a-peptide und antikörper | |
| EP2726614A4 (de) | Verbesserung der herstellung von fremdproteinen | |
| IL266073B (en) | Heterodimeric antibody fccontaining proteins and methods for production thereof | |
| HK1211952A1 (en) | Recombinant protein | |
| GB201121226D0 (en) | Modified proteins and peptides | |
| GB201121233D0 (en) | Modified proteins and peptides |